Iovance Therapeutics’ stock dropped more than 44% on Friday afternoon, a day after the company slashed its 2025 sales ...

Revolution Medicines reports positive data for KRAS-targeting cancer drug elironrasib, showing higher response rates vs Amgen ...

Wel­come back to End­points Week­ly — thanks for start­ing your Sat­ur­day with us. It was a busy week in the bio­phar­ma world. FDA Com­mis­sion­er Mar­ty Makary … ...

Insilico Medicine files third HKEX IPO attempt, as biotech develops rentosertib for IPF and other drugs with AI-driven ...

Illumina on Thursday said the SEC has closed its investigation into the company's $8 billion purchase of Grail and doesn't ...

Patrik Jonsson becomes International president, Ilya Yuffa leads USA division, Kenneth Custer takes over Cardiometabolic ...

Endpoints platform launches new profile system with improved account management features, including streamlined newsletter ...

AstraZeneca lost its challenge to Medicare drug price negotiations in the first appeals court ruling on the merits of the ...

Corvus Pharmaceuticals reported new Phase 1 data in atopic dermatitis that sent its stock price up by as much as 35% ...

Lan­theus fi­nal­ly came clean about the fate of its ex­per­i­men­tal ra­dio­phar­ma­ceu­ti­cal for prostate can­cer, ...

Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line ...

The AI-fo­cused biotech in­sitro has laid off 22% of its work­force, the com­pa­ny said in a Thurs­day state­ment. Found­ed ...